Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
Resistance to the tyrosine kinase inhibitor Sorafenib, which is the standard treatment for advanced hepatocellular carcinoma, is a major clinical challenge. Here, the authors show that phosphoglycerate dehydrogenase, a key enzyme in the serine synthesis pathway, drives sorafenib resistance.
Bibliographic Details
| Main Authors: |
Lai Wei,
Derek Lee,
Cheuk-Ting Law,
Misty Shuo Zhang,
Jialing Shen,
Don Wai-Ching Chin,
Allen Zhang,
Felice Ho-Ching Tsang,
Ceci Lok-Sze Wong,
Irene Oi-Lin Ng,
Carmen Chak-Lui Wong,
Chun-Ming Wong |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Publishing Group
2019-10-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-019-12606-7
|
|---|
